The Global Antibody-Mediated Rejection (AMR) Prevention Industry is poised to achieve a significant valuation of US$ 89 million in 2023, as highlighted in the latest report published by Future Market Insights (FMI). The report indicates an impressive compound annual growth rate (CAGR) of 16% over the forecast period.
Over the past decade, the AMR market has witnessed substantial growth, with the complement system emerging as a pivotal component. Technological advancements, particularly in genomic research and donor-specific antibody identification and definition assays, have played a pivotal role in unraveling critical insights into the pathophysiology and treatment of severe antibody-mediated rejection. This progress has significantly contributed to the expansion of the antibody-mediated rejection prevention industry.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16632
The citizenry with end-stage renal impairment is getting older. As in almost half of all new patient populations exceed the age of 65, and one-third are over the age of 70. As a consequence, late kidney transplant failure is pervasive in older people, which is anticipated to propel the antibody-mediated rejection prevention market over the coming years. According to a Pew Research Center report, the aged population in the United States will augment to 81 million by 2050, up from 37 million in 2005. As a result, this factor is expected to contribute to market expansion.
Key Takeaways from the Global Antibody-Mediated Rejection Prevention Industry Study
- The immunomodulators market is expected to grow at a CAGR of 6.3% over the forecast period.
- From 2018 to 2022, sales increased significantly at a CAGR of 14%.
- The global monoclonal antibodies segment was worth US$ 186 million in 2021
- The global monoclonal antibodies segment is expected to grow at a CAGR of 11% between 2023 and 2033.
- The global market for antibody-mediated rejection prevention is expected to be worth US$ 528.31 million.
“The population of people with end-stage kidney disease is getting older. Nearly half of all new patient populations are over 65, with one-third being over 70. As a result, late kidney transplant failure is common among the elderly, which is expected to drive the antibody-mediated rejection prevention market,” says the FMI analyst.
Ask Us Your Questions About This Report https://www.futuremarketinsights.com/ask-question/rep-gb-16632
Key Global Antibody-Mediated Rejection Prevention Industry Players
Key players in the Antibody-mediated Rejection Prevention market are CSL Behring, Hansa Biopharma, Sanofi, Talaris Therapeutics, Horizon Therapeutics, Novartis AG, Biogen, Teva Pharmaceutical Industries Ltd., Eli Lilly, and Company, Bristol-Myers & Squibb Company. Some of the latest developments are below:
- Horizon Therapeutics plc disclosed in February 2021 that it will purchase Viela Bio, Inc. to substantially expand its product portfolio and flourish its rare disease medical portfolio.
- The trial’s Independent Data Monitoring Committee has recommended that the evaluation of Jardiance® (empagliflozin) in grownups with chronic kidney disease (CKD) be halted early. Following an official interim analysis that fulfilled predefined criteria for favorable efficacy, the Medical Research Council (MRC) Population Health Research Unit reported in March 2022.
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the Global Antibody-Mediated Rejection Prevention Industry, providing historical data for 2018-2022 and forecast statistics from 2023-2033.
To understand opportunities in the Global Antibody-Mediated Rejection Prevention Industry, the market is segmented based on By Treatment (Monoclonal Antibodies, Cysteine Protease Inhibitors, Immunomodulators, Plasmapheresis), End User (Hospitals, Specialty Clinics) across five major regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).
Grab Your Report on Discount Before It’s Gone! https://www.futuremarketinsights.com/request-discount/rep-gb-16632
Key Segments Profiled in the Global Antibody-Mediated Rejection Prevention Industry Survey
By Treatment:
- Monoclonal Antibodies
- Cysteine Protease Inhibitors
- Immunomodulators
- Plasmapheresis
By End User:
- Hospitals
- Specialty Clinics
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
